Ajanta Pharma reported a consolidated net profit of ₹334.22 crore for the quarter ended June 30, 2026, representing a 30.9% year-on-year increase from ₹255.34 crore in Q1FY25. The growth was underpinned by a 24.8% rise in total income from operations to ₹1,625.96 crore, up from ₹1,302.65 crore in the prior-year period. This performance signals strong operational momentum heading into the second quarter of the fiscal year.

The Board of Directors approved the unaudited financial results at its meeting held on July 30, 2026, in compliance with Regulation 33 read with Regulation 47(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Alongside the results, the Board declared a first interim dividend of ₹399.79 crore for financial year 2026-27, translating to ₹32 per share on the face value of ₹2 per share.

Financial Performance Overview

Consolidated earnings before tax stood at ₹446.80 crore, compared to ₹331.13 crore in Q1FY25. Standalone net profit after tax rose 23.7% to ₹315.47 crore from ₹254.97 crore in the previous year’s first quarter. Standalone revenue from operations increased 23.2% to ₹1,488.67 crore against ₹1,208.56 crore recorded in Q1FY25.

Earnings per share on a basic consolidated basis reached ₹26.72, up from ₹20.43 in Q1FY25. Total comprehensive income for the consolidated entity was ₹329.96 crore, compared to ₹255.50 crore in the same quarter last year.

What the Numbers Show

The divergence between revenue growth (24.8%) and profit growth (30.9%) indicates an expansion in operating margins during the quarter. With profit before tax rising at a faster clip than top-line sales, the company appears to have benefited from improved cost efficiency or a favorable product mix shift. The substantial interim dividend payout of ₹399.79 crore further underscores management’s confidence in cash flow generation capabilities for the remainder of FY27.

Ajanta Pharma has uploaded the audio recording of its earnings call for the first quarter of FY27 (Q1FY27) on its official website. The conference call was held on July 30, 2026, at 4:15 p.m., providing investors and analysts with management commentary on the company’s financial performance for the quarter ended June 30, 2026.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. This regulation mandates listed entities to provide access to earnings call recordings to ensure transparency and equal information dissemination among stakeholders. The audio file is hosted directly on the company's investor relations portal.

Accessing the Recording

Investors can access the audio recording through the following link provided in the exchange filing:

The company stated that a written transcript of the proceedings will be submitted to the stock exchanges in due course. This transcript will offer a text-based record of the questions asked by analysts and the responses provided by management, complementing the audio recording.

Regulatory Compliance

The filing was signed by Gaurang Chinubhai Shah, Senior Vice President – Legal & Company Secretary at Ajanta Pharma. The notice was simultaneously dispatched to both the BSE Limited and the National Stock Exchange of India, ensuring compliance with listing obligations across both platforms.

This release serves as an informational update for shareholders and market participants who were unable to attend the live call. It ensures that all investors have the opportunity to review management’s perspective on the quarter’s performance, including any guidance or strategic updates discussed during the session.